Time to potential for listing of new drugs on public and private formularies in Canada: a cross-sectional study.

ABSTRACT:

Background

Information about the timing involved in various stages of making new drugs available to Canadians is important for understanding how a national pharmacare plan will affect timely access to new drugs. I explored the timing of the various steps between receiving a Notice of Compliance and a decision by the pan-Canadian Pharmaceutical Alliance (pCPA).

Methods

I gathered data from various databases (Canadian and other) about new drugs approved between 2011 and 2020, including generic names, date of application for approval (New Drug Submission [NDS]), date of Notice of Compliance, date of marketing, dates when a submission was made to the Canadian Agency for Drugs and Technologies in Health (CADTH) and the pCPA, and when these agencies made a decision.

Results

SUBMITTER: Lexchin J 

PROVIDER: S-EPMC9671297 | biostudies-literature | 2022 Oct-Dec

REPOSITORIES: biostudies-literature